Ionis Pharmaceuticals, Inc. Research and Development Expense
Ionis Pharmaceuticals, Inc. (IONS) reported Research and Development Expense of $915.62 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-02-26
- Ionis Pharmaceuticals, Inc. research and development expense for the quarter ending 2013-12-31 was $50.90M, a 23.54% increase year-over-year.
- Ionis Pharmaceuticals, Inc. research and development expense for the quarter ending 2013-09-30 was $45.00M, a 26.40% increase year-over-year.
- Ionis Pharmaceuticals, Inc. research and development expense for the quarter ending 2013-06-30 was $42.63M, a 5.43% increase year-over-year.
- Ionis Pharmaceuticals, Inc. research and development expense for the quarter ending 2013-03-31 was $38.31M, a 1.04% decline year-over-year.
- Ionis Pharmaceuticals, Inc. research and development expense for fiscal 2025 was $915.62M, a 1.56% increase from fiscal 2024.
- Ionis Pharmaceuticals, Inc. research and development expense for fiscal 2024 was $901.53M, a 0.21% increase from fiscal 2023.
- Ionis Pharmaceuticals, Inc. research and development expense for fiscal 2023 was $899.63M.
- Ionis Pharmaceuticals, Inc. research and development expense for fiscal 2021 was $638.20M, a 20.19% increase from fiscal 2020.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $915.62M 10-K · filed 2026-02-26 | ||||||
| 2024-12-31 | $901.53M 10-K · filed 2026-02-26 | ||||||
| 2023-12-31 | $899.63M 10-K · filed 2026-02-26 | ||||||
| 2021-12-31 | $638.20M 10-K · filed 2022-02-25 | ||||||
| 2020-12-31 | $531.00M 10-K · filed 2022-02-25 | ||||||
| 2019-12-31 | $461.50M 10-K · filed 2022-02-25 | ||||||
| 2018-12-31 | $411.90M 10-K · filed 2021-02-24 | ||||||
| 2017-12-31 | $372.50M 10-K · filed 2020-03-02 | ||||||
| 2016-12-31 | $340.40M 10-K · filed 2019-03-01 | ||||||
| 2015-12-31 | $319.50M 10-K · filed 2018-02-28 | ||||||
| 2014-12-31 | $238.90M 10-K · filed 2017-03-01 | ||||||
| 2013-12-31 | $50.90M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $95.90M derived: sum of 2 quarters · filed 2016-02-26 | $138.53M derived: sum of 3 quarters · filed 2016-02-26 | $173.70M 10-K · filed 2016-02-26 | |||
| 2013-09-30 | $45.00M 10-Q · filed 2013-11-05 | $87.63M derived: sum of 2 quarters · filed 2013-11-05 | $122.80M 10-Q · filed 2013-11-05 | $167.14M derived: sum of 4 quarters · filed 2015-03-02 | |||
| 2013-06-30 | $42.63M 10-Q · filed 2013-08-06 | $80.94M 10-Q · filed 2013-08-06 | $122.14M derived: sum of 3 quarters · filed 2015-03-02 | $157.74M derived: sum of 4 quarters · filed 2015-03-02 | |||
| 2013-03-31 | $38.31M 10-Q · filed 2013-05-07 | $79.51M derived: sum of 2 quarters · filed 2015-03-02 | $115.11M derived: sum of 3 quarters · filed 2015-03-02 | $155.55M derived: sum of 4 quarters · filed 2015-03-02 | |||
| 2012-12-31 | $41.20M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $76.80M derived: sum of 2 quarters · filed 2015-03-02 | $117.23M derived: sum of 3 quarters · filed 2015-03-02 | $154.60M 10-K · filed 2015-03-02 | $158.46M 10-K · filed 2013-02-28 | ||
| 2012-09-30 | $35.60M 10-Q · filed 2013-11-05 | $36.55M 10-Q · filed 2012-11-06 | $76.03M derived: sum of 2 quarters · filed 2013-11-05 | $113.40M 10-Q · filed 2013-11-05 | $115.70M 10-Q · filed 2012-11-06 | $157.67M derived: sum of 4 quarters · filed 2014-03-03 | |
| 2012-06-30 | $40.44M 10-Q · filed 2013-08-06 | $79.15M 10-Q · filed 2013-08-06 | $122.07M derived: sum of 3 quarters · filed 2014-03-03 | $162.00M derived: sum of 4 quarters · filed 2014-03-03 | |||
| 2012-03-31 | $38.71M 10-Q · filed 2013-05-07 | $81.64M derived: sum of 2 quarters · filed 2014-03-03 | $121.56M derived: sum of 3 quarters · filed 2014-03-03 | $157.57M derived: sum of 4 quarters · filed 2014-03-03 | |||
| 2011-12-31 | $42.92M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $82.85M derived: sum of 2 quarters · filed 2014-03-03 | $118.86M derived: sum of 3 quarters · filed 2014-03-03 | $153.10M 10-K · filed 2014-03-03 | $157.40M 10-K · filed 2012-02-29 | ||
| 2011-09-30 | $39.92M 10-Q · filed 2012-11-06 | $75.93M derived: sum of 2 quarters · filed 2012-11-06 | $110.18M 10-Q · filed 2012-11-06 | $149.51M derived: sum of 4 quarters · filed 2013-02-28 | |||
| 2011-06-30 | $36.01M 10-Q · filed 2012-08-06 | $70.25M 10-Q · filed 2012-08-06 | $109.59M derived: sum of 3 quarters · filed 2013-02-28 | $144.30M derived: sum of 4 quarters · filed 2013-02-28 | |||
| 2011-03-31 | $34.24M 10-Q · filed 2012-05-09 | $73.58M derived: sum of 2 quarters · filed 2013-02-28 | $108.29M derived: sum of 3 quarters · filed 2013-02-28 | $147.42M derived: sum of 4 quarters · filed 2013-02-28 | |||
| 2010-12-31 | $39.33M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $74.05M derived: sum of 2 quarters · filed 2013-02-28 | $113.17M derived: sum of 3 quarters · filed 2013-02-28 | $145.16M 10-K · filed 2013-02-28 | |||
| 2010-09-30 | $34.72M 10-Q · filed 2011-11-08 | $73.84M derived: sum of 2 quarters · filed 2011-11-08 | $105.83M 10-Q · filed 2011-11-08 | $145.93M derived: sum of 4 quarters · filed 2012-02-29 | |||
| 2010-06-30 | $39.12M 10-Q · filed 2011-08-08 | $71.11M 10-Q · filed 2011-08-08 | $111.22M derived: sum of 3 quarters · filed 2012-02-29 | $145.05M derived: sum of 4 quarters · filed 2012-02-29 | |||
| 2010-03-31 | $31.99M 10-Q · filed 2011-05-06 | $72.09M derived: sum of 2 quarters · filed 2012-02-29 | $105.92M derived: sum of 3 quarters · filed 2012-02-29 | $138.07M derived: sum of 4 quarters · filed 2012-02-29 | |||
| 2009-12-31 | $40.10M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $73.94M derived: sum of 2 quarters · filed 2012-02-29 | $106.08M derived: sum of 3 quarters · filed 2012-02-29 | $134.62M 10-K · filed 2012-02-29 | |||
| 2009-09-30 | $33.83M 10-Q · filed 2010-11-05 | $65.98M derived: sum of 2 quarters · filed 2010-11-05 | $94.52M 10-Q · filed 2010-11-05 | ||||
| 2009-06-30 | $32.15M 10-Q · filed 2010-08-09 | $60.69M 10-Q · filed 2010-08-09 | |||||
| 2008-12-31 | $106.44M 10-K · filed 2011-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |